
Alkermes plc: shareholders and insiders
Price
$47.03
November 13, 2026Market cap $7.8B
What Ploutos Investor adds for Alkermes
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 16, 2025 to Nov 3, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$10M
7 people
From Nov 16, 2025 to Nov 16, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan71%
- The rest29%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 16, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $9.9M by 7 people
- 2025: no buys, sold $229.6K by 1 person
- 2026: no buys, sold $9.9M by 7 people
- Nov 3, 2026David Joseph GaffinEVP, CLO, Alkermes, Inc.Kind10b5-1
- Oct 8, 2026Joshua ReedSVP, Chief Financial OfficerKind
- Oct 8, 2026Joshua ReedSVP, Chief Financial OfficerKind
- Oct 2, 2026David Joseph GaffinEVP, CLO, Alkermes, Inc.Kind10b5-1
- Sep 3, 2026David Joseph GaffinEVP, CLO, Alkermes, Inc.Kind10b5-1
- Sep 1, 2026Craig C. HopkinsonEVP R&D, Chief Medical OfficerKind10b5-1
- Sep 1, 2026Craig C. HopkinsonEVP R&D, Chief Medical OfficerKind10b5-1
- Aug 17, 2026Christian Todd NicholsSVP, Chief Commercial OfficerKind10b5-1
- Aug 17, 2026Christian Todd NicholsSVP, Chief Commercial OfficerKind10b5-1
- Aug 3, 2026nancy lynn MD snydermanDirectorKind
- Aug 3, 2026nancy lynn MD snydermanDirectorKind
- Aug 3, 2026nancy lynn MD snydermanDirectorKind
- Aug 3, 2026Craig C. HopkinsonEVP R&D, Chief Medical OfficerKind10b5-1
- Aug 3, 2026Craig C. HopkinsonEVP R&D, Chief Medical OfficerKind10b5-1
- Aug 3, 2026Craig C. HopkinsonEVP R&D, Chief Medical OfficerKind10b5-1
- Aug 3, 2026David Joseph GaffinEVP, CLO, Alkermes, Inc.Kind10b5-1
- Jul 6, 2026David Joseph GaffinEVP, CLO, Alkermes, Inc.Kind10b5-1
- Jul 1, 2026Craig C. HopkinsonEVP R&D, Chief Medical OfficerKind10b5-1
- Jul 1, 2026Craig C. HopkinsonEVP R&D, Chief Medical OfficerKind10b5-1
- Jul 1, 2026Craig C. HopkinsonEVP R&D, Chief Medical OfficerKind10b5-1
- Jun 12, 2026Christopher I WrightDirectorKind10b5-1
- Jun 4, 2026David Joseph GaffinEVP, CLO, Alkermes, Inc.Kind10b5-1
- Jun 1, 2026Craig C. HopkinsonEVP R&D, Chief Medical OfficerKind10b5-1
- Jun 1, 2026Craig C. HopkinsonEVP R&D, Chief Medical OfficerKind10b5-1
- May 29, 2026Samuel Joseph ParisiVP, Finance (Interim PAO)Kind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | David Joseph GaffinEVP, CLO, Alkermes, Inc. | 10b5-1 | 2,035 | $46.17 | $94.0K | Form 4 |
| Oct 8, 2026 | Joshua ReedSVP, Chief Financial Officer | 9,164 | – | – | Form 4 | |
| Oct 8, 2026 | Joshua ReedSVP, Chief Financial Officer | 4,069 | $40.11 | $163.2K | Form 4 | |
| Oct 2, 2026 | David Joseph GaffinEVP, CLO, Alkermes, Inc. | 10b5-1 | 2,034 | $41.03 | $83.5K | Form 4 |
| Sep 3, 2026 | David Joseph GaffinEVP, CLO, Alkermes, Inc. | 10b5-1 | 2,034 | $48.01 | $97.7K | Form 4 |
| Sep 1, 2026 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 10b5-1 | 5,000 | $24.59 | $123.0K | Form 4 |
| Sep 1, 2026 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 10b5-1 | 9,000 | $46.99 | $422.9K | Form 4 |
| Aug 17, 2026 | Christian Todd NicholsSVP, Chief Commercial Officer | 10b5-1 | 6,912 | $49.19 | $340.0K | Form 4 |
| Aug 17, 2026 | Christian Todd NicholsSVP, Chief Commercial Officer | 10b5-1 | 664 | $49.65 | $33.0K | Form 4 |
| Aug 3, 2026 | nancy lynn MD snydermanDirector | 27.9K | $46.72 | $1.3M | Form 4 | |
| Aug 3, 2026 | nancy lynn MD snydermanDirector | 16.5K | $46.72 | $772.0K | Form 4 | |
| Aug 3, 2026 | nancy lynn MD snydermanDirector | 44.5K | $50.35 | $2.2M | Form 4 | |
| Aug 3, 2026 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 10b5-1 | 104 | $19.34 | $2.0K | Form 4 |
| Aug 3, 2026 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 10b5-1 | 4,896 | $24.59 | $120.4K | Form 4 |
| Aug 3, 2026 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 10b5-1 | 9,000 | $48.58 | $437.2K | Form 4 |
| Aug 3, 2026 | David Joseph GaffinEVP, CLO, Alkermes, Inc. | 10b5-1 | 2,034 | $48.58 | $98.8K | Form 4 |
| Jul 6, 2026 | David Joseph GaffinEVP, CLO, Alkermes, Inc. | 10b5-1 | 2,034 | $54.03 | $109.9K | Form 4 |
| Jul 1, 2026 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 10b5-1 | 5,000 | $19.34 | $96.7K | Form 4 |
| Jul 1, 2026 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 10b5-1 | 8,300 | $51.46 | $427.1K | Form 4 |
| Jul 1, 2026 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 10b5-1 | 700 | $52.13 | $36.5K | Form 4 |
| Jun 12, 2026 | Christopher I WrightDirector | 10b5-1 | 2,000 | $45.10 | $90.2K | Form 4 |
| Jun 4, 2026 | David Joseph GaffinEVP, CLO, Alkermes, Inc. | 10b5-1 | 2,034 | $43.05 | $87.6K | Form 4 |
| Jun 1, 2026 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 10b5-1 | 5,000 | $19.34 | $96.7K | Form 4 |
| Jun 1, 2026 | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 10b5-1 | 9,000 | $41.67 | $375.0K | Form 4 |
| May 29, 2026 | Samuel Joseph ParisiVP, Finance (Interim PAO) | 3,392 | $20.03 | $67.9K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 22, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by ALKS's officers and directors from 2011 up to November 15, 2025, 15 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 10 more, back to 2011
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class15.8%
- Baker Bros. Advisors LPwith 3 more personsShare of class6.10%
- Vanguard Portfolio ManagementShare of class5.80%
- Vanguard Capital ManagementShare of class5.21%
- State StreetShare of class5.20%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 15.8% | 25.64M | Apr 28, 2025 | 13G/A | |
| Baker Bros. Advisors LPwith 3 more persons | 6.10% | 10.01M | Feb 17, 2026 | 13G | |
| Vanguard Portfolio Management | 5.80% | 9.65M | Apr 28, 2026 | 13G | |
| Vanguard Capital Management | 5.21% | 8.68M | Apr 28, 2026 | 13G | |
| State Street | 5.20% | 8.54M | Nov 10, 20252 filings since May 13, 2025 | 13G |
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Renaissance TechnologiesIn the quarter+0.5%
- Citadel Advisors (Griffin)In the quarter-27%
- D.E. ShawIn the quarter+85%
- Bridgewater (Dalio)In the quarter
- Millennium Mgmt (Englander)In the quarter
- AQR CapitalIn the quarter-45%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Renaissance Technologies | 6.49M | +0.5% | $263M | 0.36% |
| Citadel Advisors (Griffin) | 1.65M | -27% | $86M | 0.05% |
| D.E. Shaw | 1.31M | +85% | $69M | 0.04% |
| Bridgewater (Dalio) | – | – | 0.01% | |
| Millennium Mgmt (Englander) | 319.6K | $17M | 0.01% | |
| AQR Capital | 213.0K | -45% | $11M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 11.4% of its shares outstanding were held short, +6.9% since the report before.
- Shares held short
- 19.05M
- 11.4%
- Since the report before17.82M on Sep 30, 2026
- +6.9%
- 9.1
- 2.09M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 88%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 7.99M
- Nov 15, 2023: Shares held short 7.96M
- Nov 30, 2023: Shares held short 7.78M
- Dec 15, 2023: Shares held short 9.68M
- Dec 29, 2023: Shares held short 14.02M
- Jan 12, 2024: Shares held short 13.23M
- Jan 31, 2024: Shares held short 11.66M
- Feb 15, 2024: Shares held short 12.22M
- Feb 29, 2024: Shares held short 13.02M
- Mar 15, 2024: Shares held short 14.08M
- Mar 28, 2024: Shares held short 14.34M
- Apr 15, 2024: Shares held short 13.52M
- Apr 30, 2024: Shares held short 12.89M
- May 15, 2024: Shares held short 12.94M
- May 31, 2024: Shares held short 11.73M
- Jun 14, 2024: Shares held short 11.96M
- Jun 28, 2024: Shares held short 13.68M
- Jul 15, 2024: Shares held short 16.13M
- Jul 31, 2024: Shares held short 18.54M
- Aug 15, 2024: Shares held short 17.70M
- Aug 30, 2024: Shares held short 17.19M
- Sep 13, 2024: Shares held short 18.62M
- Sep 30, 2024: Shares held short 17.18M
- Oct 15, 2024: Shares held short 15.82M
- Oct 31, 2024: Shares held short 16.12M
- Nov 15, 2024: Shares held short 16.56M
- Nov 29, 2024: Shares held short 13.71M
- Dec 13, 2024: Shares held short 12.50M
- Dec 31, 2024: Shares held short 10.74M
- Jan 15, 2025: Shares held short 11.37M
- Jan 31, 2025: Shares held short 10.82M
- Feb 14, 2025: Shares held short 11.57M
- Feb 28, 2025: Shares held short 14.01M
- Mar 14, 2025: Shares held short 12.95M
- Mar 31, 2025: Shares held short 11.00M
- Apr 15, 2025: Shares held short 12.35M
- Apr 30, 2025: Shares held short 12.76M
- May 15, 2025: Shares held short 11.27M
- May 30, 2025: Shares held short 11.56M
- Jun 13, 2025: Shares held short 10.56M
- Jun 30, 2025: Shares held short 11.86M
- Jul 15, 2025: Shares held short 12.57M
- Jul 31, 2025: Shares held short 13.82M
- Aug 15, 2025: Shares held short 13.81M
- Aug 29, 2025: Shares held short 13.31M
- Sep 15, 2025: Shares held short 15.06M
- Sep 30, 2025: Shares held short 15.21M
- Oct 15, 2025: Shares held short 14.40M
- Oct 31, 2025: Shares held short 15.90M
- Nov 14, 2025: Shares held short 17.30M
- Nov 28, 2025: Shares held short 18.83M
- Dec 15, 2025: Shares held short 20.03M
- Dec 31, 2025: Shares held short 21.84M
- Jan 15, 2026: Shares held short 21.67M
- Jan 30, 2026: Shares held short 19.00M
- Feb 13, 2026: Shares held short 17.82M
- Feb 27, 2026: Shares held short 18.20M
- Mar 13, 2026: Shares held short 20.60M
- Mar 31, 2026: Shares held short 19.01M
- Apr 15, 2026: Shares held short 19.68M
- Apr 30, 2026: Shares held short 19.76M
- May 15, 2026: Shares held short 18.28M
- May 29, 2026: Shares held short 17.36M
- Jun 15, 2026: Shares held short 17.96M
- Jun 30, 2026: Shares held short 17.46M
- Jul 15, 2026: Shares held short 15.02M
- Jul 31, 2026: Shares held short 14.41M
- Aug 14, 2026: Shares held short 14.76M
- Aug 31, 2026: Shares held short 14.72M
- Sep 15, 2026: Shares held short 15.16M
- Sep 30, 2026: Shares held short 17.82M
- Oct 15, 2026: Shares held short 19.05M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading57.4% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 57.4% of the shares in the reported trades were short sales, against 66.3% in the 14 before.
- Last 14 sessionsOct 27, 2026 – Nov 13, 2026
- 57.4%
- The 14 beforeOct 7, 2026 – Oct 26, 2026
- 66.3%
- Change
- -8.9 pts
- Short sales a dayon average, of 650.0K shares
- 373.1K
- More than atof 3,649 US-listed companies, same days
- 76%
- Median of alleight in ten from 34.6% to 63.4%
- 50.1%
- Short sales
- Oct 7, 2026: Short sales 58.2%
- Oct 8, 2026: Short sales 69.2%
- Oct 9, 2026: Short sales 70.8%
- Oct 12, 2026: Short sales 82.2%
- Oct 13, 2026: Short sales 68.1%
- Oct 14, 2026: Short sales 56.9%
- Oct 15, 2026: Short sales 79.5%
- Oct 16, 2026: Short sales 61%
- Oct 19, 2026: Short sales 65.1%
- Oct 20, 2026: Short sales 62.5%
- Oct 21, 2026: Short sales 45.9%
- Oct 22, 2026: Short sales 60.1%
- Oct 23, 2026: Short sales 74.9%
- Oct 26, 2026: Short sales 64%
- Oct 27, 2026: Short sales 64.9%
- Oct 28, 2026: Short sales 55%
- Oct 29, 2026: Short sales 51.2%
- Oct 30, 2026: Short sales 67.7%
- Nov 2, 2026: Short sales 65.3%
- Nov 3, 2026: Short sales 39.8%
- Nov 4, 2026: Short sales 63.2%
- Nov 5, 2026: Short sales 46.1%
- Nov 6, 2026: Short sales 72.1%
- Nov 9, 2026: Short sales 41.1%
- Nov 10, 2026: Short sales 67.9%
- Nov 11, 2026: Short sales 71.2%
- Nov 12, 2026: Short sales 56.7%
- Nov 13, 2026: Short sales 66.7%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- David Joseph GaffinEVP, CLO, Alkermes, Inc.Directly219.4K
- Shane CookeDirectorDirectly106.7K
- Christian Todd NicholsSVP, Chief Commercial OfficerDirectly102.2K
- Craig C. HopkinsonEVP R&D, Chief Medical OfficerDirectly65.4K
- Brian P MckeonDirectorDirectly48.5K
- nancy lynn MD snydermanDirectorDirectly36.2K
- Frank Anders WilsonDirectorDirectly35.8K
- Richard GaynorDirectorDirectly35.8K
- Cato T LaurencinDirectorDirectly33.8K
- Christopher I WrightDirectorDirectly25.7K
- Nancy LurkerDirectorDirectly18.2K
- Samuel Joseph ParisiVP, Finance (Interim PAO)Directly7,717
- Joshua ReedSVP, Chief Financial OfficerDirectly5,095
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| David Joseph GaffinEVP, CLO, Alkermes, Inc. | 219.4K | – | Nov 3, 2026 | Form 4 |
| Shane CookeDirector | 106.7K | – | May 21, 2026 | Form 4 |
| Christian Todd NicholsSVP, Chief Commercial Officer | 102.2K | – | Aug 17, 2026 | Form 4 |
| Craig C. HopkinsonEVP R&D, Chief Medical Officer | 65.4K | – | Sep 1, 2026 | Form 4 |
| Brian P MckeonDirector | 48.5K | – | May 21, 2026 | Form 4 |
| nancy lynn MD snydermanDirector | 36.2K | – | Aug 3, 2026 | Form 4 |
| Frank Anders WilsonDirector | 35.8K | – | May 21, 2026 | Form 4 |
| Richard GaynorDirector | 35.8K | – | May 21, 2026 | Form 4 |
| Cato T LaurencinDirector | 33.8K | – | May 21, 2026 | Form 4 |
| Christopher I WrightDirector | 25.7K | – | Jun 12, 2026 | Form 4 |
| Nancy LurkerDirector | 18.2K | – | May 21, 2026 | Form 4 |
| Samuel Joseph ParisiVP, Finance (Interim PAO) | 7,717 | – | May 29, 2026 | Form 4 |
| Joshua ReedSVP, Chief Financial Officer | 5,095 | – | Oct 8, 2026 | Form 4 |
A lower bound: it counts only the 13 officers and directors with a market trade since Nov 17, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund1.11%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.76%
- IBBiShares Biotechnology ETFWeight in the fund0.67%
- SPSMState Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETFWeight in the fund0.47%
- IJRiShares Core S&P Small-Cap ETFWeight in the fund0.47%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.42%
- IWMiShares Russell 2000 ETFWeight in the fund0.27%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.25%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.25%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.16%
25 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 359
- Q4 2025: Managers 367
- Q1 2026: Managers 392
- Q2 2026: Managers 425
Institutional investors by quarter
The fund managers holding ALKS, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 425 managers held 178M shares, worth $9.3B. During the quarter 89 opened a position, 56 closed one, 133 added and 135 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+3.3%
- Baker Bros. AdvisorsIn the quarter
- Vanguard Portfolio ManagementIn the quarter-0.2%
- State StreetIn the quarter-3.2%
- Vanguard Capital ManagementIn the quarter+1.2%
- Price T Rowe AssociatesIn the quarter+44%
- Renaissance TechnologiesIn the quarter+4.9%
- Geode Capital ManagementIn the quarter+7.1%
- Dimensional Fund AdvisorsIn the quarter-7.2%
- Deep Track CapitalIn the quarter+11%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 29.24M | +3.3% | $1.5B |
| Baker Bros. Advisors | 10.01M | $525M | |
| Vanguard Portfolio Management | 9.49M | -0.2% | $497M |
| State Street | 9.16M | -3.2% | $480M |
| Vanguard Capital Management | 7.52M | +1.2% | $394M |
| Price T Rowe Associates | 6.74M | +44% | $353M |
| Renaissance Technologies | 6.46M | +4.9% | $339M |
| Geode Capital Management | 4.48M | +7.1% | $235M |
| Dimensional Fund Advisors | 4.19M | -7.2% | $220M |
| Deep Track Capital | 4.00M | +11% | $210M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Alkermes's filings show?
Who buys and sells is one part of Alkermes's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have ALKS's insiders bought or sold?
From May 22, 2026 to Nov 3, 2026 Alkermes's insiders bought 0 and sold $5.7M of shares on the market. 48% of the sales were under set 10b5-1 plans.
Which well-known managers hold ALKS?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $263M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.